Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Volume: 16, Issue: 6, Pages: 341 - 355
Published: Jun 1, 2019
Abstract
The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-based evidence of molecular pathway and/or oncogene addiction of the tumour became mandatory for the allocation of specific targeted therapies. More recently, the immunotherapy revolution, specifically, the development of immune-checkpoint inhibitors (ICIs), has dramatically altered the NSCLC treatment landscape. Herein, we compare and...
Paper Details
Title
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Published Date
Jun 1, 2019
Volume
16
Issue
6
Pages
341 - 355
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.